Sabrina Johnson.

Sabrina Johnson is the Founder and CEO of Daré Bioscience, a publicly traded women's health pharmaceutical company focused on developing and commercializing innovative products for reproductive health and sexual wellness.

Johnson founded Daré in 2015 to address the persistent underinvestment in women's health pharmaceutical innovation. Under her leadership, Daré has built a portfolio addressing women's unmet needs including contraception, fertility, menopause, and vulvovaginal disorders. The company's products include Xaciato (treatment for bacterial vaginosis), Ovaprene (a hormone-free contraceptive in development), and multiple other candidates. Johnson has dedicated her entire career to women's health, previously holding leadership roles at other women's health companies including WomanCare Global and Cypress Bioscience. She has been recognized by multiple publications for her contributions to women's health innovation. Johnson's work addresses the historical neglect of women's health research by the pharmaceutical industry-a problem highlighted by the fact that women were not required to be included in clinical trials until 1993. Her leadership in building dedicated infrastructure for women's health pharmaceutical innovation represents important progress for an underserved market.